Caplin Point Laboratories Ltd.
CAPLIPOINT · Healthcare · Data through 22 Nov 2026
- Total delivery percentage
- 42.7%
- Total volume
- 1,65,087
- Delivery quantity
- 70,488
- Calculated intraday
- 94,599
- Exchange trades
- 17,905
Of 1,65,087 NSE traded shares, 70,488 were delivered on 22 Nov 2026.
Caplin Point Laboratories Ltd. price and volume history chart
Loading daily EOD data...
Recent delivery history
Caplin Point Laboratories Ltd.: latest 20 available trading sessions, newest first. Missing exchange values are shown as —.
| Date | Close | Total volume | Delivery quantity | Delivery % |
|---|---|---|---|---|
| ₹2,029.10 | 1,65,087 | 70,488 | 42.7% | |
| ₹2,029.10 | 1,65,087 | 70,488 | 42.7% | |
| ₹2,084.60 | 2,44,183 | 78,336 | 32.1% | |
| ₹2,085.30 | 7,10,053 | 1,85,926 | 26.2% | |
| ₹2,247.10 | 2,18,957 | 81,222 | 37.1% | |
| ₹2,346.80 | 80,857 | 36,341 | 44.9% | |
| ₹2,388.70 | 1,28,175 | 51,654 | 40.3% | |
| ₹2,388.70 | 1,28,175 | 51,654 | 40.3% | |
| ₹2,386.30 | 4,61,475 | 1,16,048 | 25.1% | |
| ₹2,520.30 | 79,579 | 39,020 | 49.0% | |
| ₹2,502.50 | 2,20,331 | 61,169 | 27.8% | |
| ₹2,502.50 | 2,20,331 | 61,169 | 27.8% | |
| ₹2,382.50 | 23,861 | 11,473 | 48.1% | |
| ₹2,382.50 | 23,861 | 11,473 | 48.1% | |
| ₹2,421.40 | 56,138 | 33,291 | 59.3% | |
| ₹2,416.10 | 57,976 | 34,926 | 60.2% | |
| ₹2,364.60 | 35,608 | 18,746 | 52.6% | |
| ₹2,336.40 | 50,041 | 27,582 | 55.1% | |
| ₹2,325.60 | 1,28,339 | 62,008 | 48.3% | |
| ₹2,325.60 | 1,28,339 | 62,008 | 48.3% |
How the volume figures are calculated
Delivery percentage is delivery quantity divided by total traded quantity, multiplied by 100. Calculated intraday quantity is total traded quantity minus delivery quantity. If the exchange does not provide delivery quantity, both delivery percentage and calculated intraday quantity remain unavailable rather than being shown as zero.
Important interpretation note
These values describe exchange-reported quantities, not unique people. Exchange trade count is not the number of buyers, sellers or intraday traders. Use the chart as a research aid and read our methodology and market-data disclaimer.